From linearized plasmid template to QC-released mRNA drug substance — every step's reagents, GMP-grade options, protocols and evidence in one place. Mix RUO for development and GMP for scale-up without changing your process.
|
No. |
Product Name |
DMF No. |
|
1 |
MF037298 |
|
|
2 |
MF037035 |
|
|
3 |
MF037433 |
|
|
4 |
MF037434 |
|
|
5 |
MF037545 |
|
|
6 |
MF037546 |
|
|
7 |
MF037607 |
|
|
8 |
MF037744 |
One Complete Solution, Plasmid to Released mRNA
mRNA IVTSolution (Two-Step Enzymatic Capping) LZCap™ One-Pot Co-Transcriptional Capping
Key Highlights
GMP-grade raw materials for in vitro mRNA synthesis and modification — animal-free and ampicillin-free.
Production, quality control, and documentation systems fully meet the R&D and manufacturing requirements for mRNA vaccines and therapeutics.
DMF filed, supporting dual regulatory submissions in China and the US.
Manufacturing facility certified to ISO 13485.
Linear mRNA Synthesis Solution
Circular mRNA Synthesis Solution
Key Step & Core Enzyme Material
Step 1. Template Preparation – Plasmid Linearization
In this step, the constructed plasmid is digested with restriction enzymes to generate a linearized double-stranded DNA template for subsequent mRNA synthesis.
1.1 Bsa I, GMP Grade(Cat#10661）
The restriction endonuclease Bsa I specifically recognizes and cleaves target sites in double-stranded DNA, linearizing template plasmids to prepare DNA templates for in vitro mRNA synthesis.
Recognition & Cleavage Site:
5'······GGTCTC(N)₁↓······3'
3'······CCAGAG(N)₅↑······5'
Product Features:
High specificity for its recognition sequence.
Cleavage is blocked by CpG and Dcm methylation (complete sequence overlap).
Cleavage may be affected by EcoBI methylation (complete sequence overlap).
Not affected by Dam methylation (no sequence overlap).
Figure 1. No non-specific nuclease residues test
20 U BsaI was incubated with substrate DNA at 37°C for 1 h and 16 h, and DNA band changes were compared by agarose gel electrophoresis. The results showed that there was no non-specific nuclease residue in BsaI.
1.2 BspQI, GMP Grade(Cat#10664)
The restriction endonuclease BspQI specifically recognizes and cleaves target sites in double-stranded DNA, linearizing template plasmids to prepare DNA templates for in vitro mRNA synthesis.
Recognition & Cleavage Site:
5'······GCTCTTC(N)₁↓······3'
3'······CGAGAAG(N)₄↑······5'
Product Features:
Insensitive to Dam, Dcm, and mammalian CpG methylation.
Isoschizomers include Lgu I, PciS I, and Sap I.
Figure 2. Comparison of Digestion Efficiency at Different Enzyme Amounts (0.125–4 U): 2 U Delivers Optimal Performance
In a 50 μL reaction system, 1 μg of λDNA was treated with the corresponding amount of BspQI (incubate at 50 °C for 60 min and then incubate at 80 °C for 20 min to inactivate BspQI). Then 20 μL of the reaction solution was loaded.
M: DNA marker
C: The control group without BspQI treatment
Step 2. In Vitro mRNA Synthesis
In this step, mRNA is synthesized in vitro using a DNA template catalyzed by RNA polymerase.
2.1 T7 RNA Polymerase, GMP Grade (Cat#10625 or 10629, low dsRNA)
mRNA can be synthesized at scale via in vitro transcription (IVT). The T7 promoter is one of the most efficient promoters, enabling rapid and high-yield RNA production with T7 RNA Polymerase. It is a key enzyme for manufacturing therapeutic mRNA.
Double-stranded RNA (dsRNA), a byproduct of IVT, can trigger innate immune responses and severely impact mRNA vaccine efficacy, requiring strict control during production. The engineered T7 RNA Polymerase mutant (Cat#10629) significantly reduces dsRNA content in the final transcript.
Product Features:
Significantly reduces dsRNA content(~1/100,000)
High yield: 150–250 μg per 20 μL reaction
High co-transcriptional capping efficiency, compatible with TriLink CleanCap AG and LZCap
Excellent integrity across transcripts of varying lengths
Figure 3. Excellent RNA integrity for transcripts of varying lengths synthesized by different T7 RNA polymerases.
The yields obtained with low‑dsRNA T7 RNA polymerase (T7 mutant) are comparable to wild‑type (WT) T7 RNA polymerase. The T7 mutant exhibits superior performance in reducing dsRNA by‑product while maintaining high RNA integrity, compared with WT and Supplier N*.
2.2 Pyrophosphatase, Inorganic (E.coli), GMP Grade (Cat#10620)
Adding inorganic pyrophosphatase during in vitro RNA synthesis increases RNA yield. It catalyzes the hydrolysis of inorganic pyrophosphate into orthophosphate (P₂O₇⁴⁻ + H₂O + PPase → 2HPO₄²⁻), which both removes pyrophosphate inhibition from the reaction system and provides thermodynamic driving force to promote product formation, significantly boosting yield in large-scale mRNA vaccine synthesis.
Figures 4. The relationship between RNA yield and IPPA concentration in vitro transcription.
2.3 Nucleotides (ATP/CTP/GTP/UTP)
Nucleoside triphosphates (NTPs) are applicable to various molecular biology applications.
Figures 5. HPLC purity profiles of NTPs
Step 3. Template Removal (DNase I, GMP Grade, Cat#10611)
This step removes the double-stranded DNA template after RNA transcription is complete.
Step 4. Post-Transcriptional RNA Modification: Capping & Tailing
This step modifies mRNA to produce fully functional mRNA molecules.
4.1 Post-Transcriptional Capping
Vaccinia Capping Enzyme (GMP Grade, Cat#10614): Catalyzes the addition of a Cap0 structure to the 5' end of in vitro transcribed RNA, significantly improving mRNA stability and translational capacity while protecting against exonuclease degradation.
mRNA Cap 2'-O-Methyltransferase (GMP Grade, Cat#10612): Converts Cap0 to Cap1 using S-adenosylmethionine (SAM) as a methyl donor. The resulting Cap1 structure is less readily recognized by the immune sensor RIG-I, reducing immunogenicity while enhancing mRNA stability and translation efficiency.
Figure 6. The capping efficiency almost reached 100% by the vaccinia capping system from YEASEN. Nucleic acid mass spectrometry before the cap reaction was shown in Figure 1A. Nucleic acid mass spectrometry after the cap reaction was shown in Figure 1B.
4.2 Co-transcriptional Capping
Compatible with TriLink CleanCap AG and LZCap systems for direct co-transcriptional incorporation of Cap1 structures, streamlining the mRNA synthesis workflow.
Figure 7. Comparision of Enzymatic capping, the next generation LZCap Capping and the first generation Capping (ARCA) method
|
Capping System |
mRNA Yield (μg) |
|
Cap AG (3'-OMe-7mG) |
164 |
|
LZCap AG (3'Acm) |
173 |
|
AG (no capping) |
200 |
Figure 8. MS analysis of the capping efficiency of LZCapped Luciferase mRNA with RNAse H based method. The capping efficiency is about 97.59%.
Circle RNA Synthesis-RNase R, GMP-grade(Cat#14615)
Figure 9. Comparison of linear mRNA digestion efficiency.
1 μg of linear mRNA was treated with Yeasen RNase R versus RNase R from supplier A and B. Yeasen RNase R showed significantly better digestion performance than the competing products.
Ready-to-Use RNA Products: Reporter/Functional Gene mRNA, circRNA, saRNA
CleanRNA™ mRNA Series features ultra-low dsRNA contaminants for reduced innate immune activation and robust protein expression in vitro and in vivo. The portfolio includes reporter mRNAs, OVA antigen-encoding mRNA, saRNA, and eSpCas9 mRNA for diverse mRNA research and genome-editing applications.
|
Product Name |
Cat. No. |
Application |
|
CleanRNA™ Firefly Luciferase mRNA |
Luciferase reporter |
|
|
CleanRNA™ mCherry mRNA |
Fluorescent reporter |
|
|
CleanRNA™ eGFP saRNA |
Targeted gene activation |
|
|
CleanRNA™ eGFP mRNA |
Fluorescent reporter |
|
|
CleanRNA™ OVA mRNA |
Antigen expression |
|
|
CleanRNA™ Firefly Luciferase saRNA |
Targeted gene activation |
|
|
eSpCas9 mRNA |
CRISPR genome editing |
Why Choose GMP-Grade Materials ?
GMP-grade materials are designed to provide greater control over critical quality attributes, manufacturing processes, and documentation—helping support the consistency and traceability required for mRNA development and manufacturing.
|
Quality Attribute |
RUO-Grade Materials |
GMP-Grade Materials |
|
Animal-Derived Components |
May be present |
Animal-origin-free options |
|
Cell Bank Characterization |
Basic |
Comprehensive characterization |
|
Raw Material Traceability |
Limited |
Full traceability |
|
Endotoxin Control |
Product dependent |
Controlled to applicable pharmacopeial requirements |
|
Antibiotics |
May be present |
Antibiotic-free options |
|
Process Validation |
Limited |
Validated manufacturing processes |
|
Change Control |
Standard |
Controlled change management |
|
Quality System |
Internal system |
ISO 13485 |
|
Regulatory Documentation |
COA |
Expanded documentation support |
|
DMF Support |
Not available |
Available for selected products |
Engineered Enzymes for Efficient IVT
At the core of mRNA synthesis is the performance of key enzymes.
Powered by the ZymeEditor™ enzyme engineering platform, Yeasen develops engineered molecular enzymes with optimized activity and application performance. Combined with high-density fermentation and the UCF.ME™ ultra-clean purification platform, our manufacturing system is designed to support:
- High enzymatic activity and High purity
- Low residual impurities
- Consistent batch-to-batch performance
- Scalable manufacturing and Reliable supply
From enzyme engineering to manufacturing, Yeasen helps build a reliable foundation for mRNA production.
Enzyme Engineering
ZymeEditor™ enables continuous development of engineered molecular enzymes with optimized performance.
Ultra-Clean Manufacturing
UCF.ME™ supports high-purity molecular enzyme production and impurity control.
Scalable Supply
Manufacturing capabilities designed to support applications from laboratory research to industrial production.
Quality & Regulatory Support
ISO 13485 quality system, comprehensive quality documentation, and DMF support for selected products.
Build Your mRNA Workflow with Yeasen
From DNA template to high-quality mRNA, Yeasen provides the critical enzymes, raw materials, and technical support to support your mRNA program.
Explore Yeasen's mRNA IVT Solutions